| Literature DB >> 34659248 |
Ana Valle-Noguera1, Anne Ochoa-Ramos1, Maria José Gomez-Sánchez1, Aranzazu Cruz-Adalia1.
Abstract
Type 3 Innate lymphoid cells (ILC3s) have been described as tissue-resident cells and characterized throughout the body, especially in mucosal sites and classical first barrier organs such as skin, gut and lungs, among others. A significant part of the research has focused on their role in combating pathogens, mainly extracellular pathogens, with the gut as the principal organ. However, some recent discoveries in the field have unveiled their activity in other organs, combating intracellular pathogens and as part of the response to viruses. In this review we have compiled the latest studies on the role of ILC3s and the molecular mechanisms involved in defending against different microbes at the mucosal surface, most of these studies have made use of conditional transgenic mice. The present review therefore attempts to provide an overview of the function of ILC3s in infections throughout the body, focusing on their specific activity in different organs.Entities:
Keywords: IL-17; IL-22; ILC3s; host-pathogen interaction; infection; mucosa; pathogens; type 3 innate lymphoid cells
Mesh:
Year: 2021 PMID: 34659248 PMCID: PMC8511434 DOI: 10.3389/fimmu.2021.748851
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Function of ILC3s against pathogens in oral mucosa. S. aureus causes the keratinocytes of the skin to produce IL-1α and IL-36α. These interleukins bind to their receptors in ILC3s and γδ T cells, inducing the production of IL-17, which promotes neutrophil infiltration.
Figure 2Role of ILC3s in the development of fibrosis induced by Hepatitis B (HBV) infection. In HBV infection, ILC3s can directly promote the expression of fibrogenic genes in hepatic stellate cells (HSC) in non-contact manners by producing IL-17A and IL-22. Additionally, ILC3s also have indirect fibrogenic effects by producing IL-22 to suppress interferon IFN-γ (an anti-fibrotic cytokine) production by other immune cells.
Figure 3Interleukins produced by ILC3s and the molecular mechanisms of their role to protect against lung pathogens. Production of IL-17 and IL-22 by ILC3s following influenza infection might decrease the susceptibility to Staphylococcus infections. Innate-like lymphocytes are involved in the production of IL-22 following A. fumigatus exposure, being IL-21 the interleukin required for the maintaining of optimal numbers of iNKT cells and ILC3s. Both IL-17 and IL-22 from ILC3s are involved in the formation of iBALT which helps fight against M. tuberculosis. Recruitment of IL-22-producing ILC3s to the lung is required for protection from S. pneumoniae infection. IL-17 production in P. aeruginosa infection might come from ILC3s and it is essential in the defense against this pathogen. The recruitment of monocytes producing TNF-α increases IL-17-secreting ILCs which has been demonstrated to be important in the clearance of K. pneumoniae. AhR is important for IDO expression within the dendritic cells (DCs) as well as their production of kynurenines (Kyn). One of Kyn’s roles is to promote the IL-22 and IL-17-producing ILC3 function in order to fight against P. brasiliensis.
Figure 4Role of ILC3s in the response against gut pathogens. The expression of RORα in ILC3s leads to intestinal fibrosis in a Crohn’s disease model of S. Typhimurium. At the same time, an up-regulation of RUNX3 expression in ILC3s promotes the IL-12/STAT4/IFN-γ signaling pathway, which is also involved in the fight against this pathogen. Cytokines produced by ILC3s promote the NFkB and STAT3 pathway, both of which are involved in the production of lipocalin-2 (LCN-2) by intestinal epithelial cells (IECs), inhibiting the growth of K. pneumoniae. The binding between LIGHT and its receptor HVEM in ILC3s promotes IFN-γ production which is involved in the defence against Y. enterocolitica. In the defence against C. difficile, acetate promotes the production of IL-1β in neutrophils via the FFAR2-NLRP3 inflammasome axis, activating ILC3s via IL-1R to produce IL-22.
Figure 5Function of IL-22-producing ILC3 cells in the development of colitis-associated colon cancer (CAC) following exposure of Candida albicans. Dectin-3, expressed by myeloid cells, recognizes this fungus and down-regulates the production of IL-7. In Dectin-3-deficient mice, macrophages display a HIF-1α-dependent glycolysis which brings ILC3s to produce IL-22 (through STAT3 and AhR), leading to the progression of CAC.
Figure 6Role of ILC3s in the response against C. rodentium. Vasoactive intestinal peptide (VIP), released by neurons in lymphoid patches in close contact with CCR6+ ILC3s, inhibits their IL-22 secretion. Simultaneously, ILC3s have a negative intrinsic modulation, expressing both RANK and RANKL, which suppresses the induction of IL-22 and IL-17. Susceptibility to C. rodentium infection is caused by these inhibitory mechanisms. The interaction between CCR6+ ILC3 and TfH cells through MHC-II in the mesenteric lymph nodes limits the TfH responses as well as pathogen specific-IgA. Simultaneously, ILC3s expression of TL1A receptor DR3 confers protection against C. rodentium. SCFAs produced by the commensal microbiota from dietary fibers increase IL-22 secretion in ILC3s via the FFAR2/FFAR3-AKT/mTOR/STAT3 molecular pathway, thus contributing to the elimination of the infection. Moreover, ILC3-derived GM-CSF production can improve antimicrobial responses by increasing the expression of IL-1β and MHC-II in macrophages (M1-like macrophages). Furthermore, Vitamins D and A in the diet increase ILC3’s synthesis of IL-22, which protects against C. rodentium; vitamin A’s molecular mechanism is via HIC (Hypermethylated in cancer 1).
Main results of the function and molecular mechanism described in each research article divided by tissue and pathogen.
| Tissue | Pathogen | Mechanism | Function | Reference |
|---|---|---|---|---|
|
|
| MyD88-dependent induction of IL-1α and IL-36α by KCs. Secretion of IL-17 by both γδ T cells and ILC3s | Skin inflammation and neutrophil infiltration | Nakagawa et al. ( |
|
|
| Induction of IL-17 by nTh17s, γδ T cells, and ILC3s | Protection | Gladiator et al. ( |
|
| Adenovirus and LCMV | Early IL-17A production by ILC3s | Protection | Jie et al. ( |
| Hepatitis B virus (HBV) | Secretion of IL-17A and IL-22 by ILC3s. Activation of HSC (regulating TGF-β receptor expression and STAT3 pathway) | Fibrosis | Wang et al. ( | |
|
| Influenza virus | IFN-β production. Inhibition of IL-17 production by T cells and potentially by ILC3s | Prevention of secondary bacterial infections | Li et al. ( |
| Induction of IL-22+ ILC3s in the lung | Induction of epithelial regeneration and protection against secondary bacterial infections | Ivanov et al. ( | ||
|
| Induction of IL-22-expressing cells | Inflammation: negative impact on lung function | Reeder et al. ( | |
|
| CXCR5-dependent iBALT formation through IL-17 and IL-22 secreted by ILC3s | Organization of protective immune responses | Ardain et al. ( | |
|
| Induction of IL-22 by ILC3s | Protection | Van Maele et al. ( | |
| Expansion and maturation of pulmonary ILC precursors mediated by IGF-1 from alveolar fibroblasts | Protection | Gray et al. ( | ||
| IL-17A expression after IL-7 prophylactic stimulation | Protection | Hassane et al. ( | ||
|
| Recruitment of monocytes-producing TNF-α. Induces IL-17-secreting ILCs, which increase ROS in the monocytes | Protection | Xiong et al. ( | |
| Secretion of IL-22 by IL-17+ IL-22+ ICOS+ ILC3s | Protection | Iwanaga et al. ( | ||
|
| Production of IL-22 by ILCs induced by previous exposure to | Induction of antimicrobial peptides and protection against | Mear et al. ( | |
| IFN-λ induction by IL-22 | Protection | Broquet et al. ( | ||
| Induction of IL-17 by innate CD3-CD19- CD11c- NK1.1- cells | Protection | Bayes et al. ( | ||
|
| IDO-1 expression and Kyn synthesis in DCs induced by AhR | Protection | Araújo et al. ( | |
|
| Simian immunodeficiency virus (SIV) | Reduction of IL-17 secretion due to NKp44+ NK (ILC3s) depletion | Not conclusive | Reeves RK et al. ( |
| Up-regulation of CD95 leads to ILC3s depletion and thus low levels of IL-22 | Intestinal barrier impairment | Guo and Fu, ( | ||
| Induction of ILC3 apoptosis through TLRs | Not conclusive | Xu et al. ( | ||
| Reduction of the expression of α4β7 integrin in colonic ILC3s | Not conclusive | Hueber et al. ( | ||
| Correlation between NKp44+ ILCs levels and delayed SIV acquisition with decreased viremia in vaccinated macaques. | Protection | Rahman et al. ( | ||
| Human immunodeficiency virus (HIV) | Reduction of ILCs in ART treated people | Not conclusive | Wang et al. ( | |
| Correlation between lower levels of ILCs and preterm birth | Not conclusive | Akoto et al. ( | ||
| Recovery of ILCs in vertically HIV-infected children only when ART is iniciated at birth | Not conclusive | Singh et al. ( | ||
|
|
| Formation of fibrosis regulated by RORα in ILC3s | Intestinal fibrosis | Lo et al. ( |
| Activation of the IL-12/STAT4/IFN-γ signaling pathway in ILC3s by Runx3 | Limitation of the intracellular bacterial infection | Yin et al. ( | ||
|
| Secretion of IL-17 by ILC3s | Not conclusive | Lee et al. ( | |
|
| Secretion of IL-17, IL-22, and TNF by ILC3s produces LCN-2 by intestinal epithelial cells | Inhibition of | Coorens et al. ( | |
| Production of IL-17A by ILC3s | Protection against sepsis by | Niu, et al. ( | ||
|
| Induction of IFNγ by ILC3s induced by HVEM’s ligand LIGHT | Protection | Seo et al. ( | |
|
| Regulation of ILC3s by hypoxia | Protection | Fachi et al. ( | |
| Production of IL-1β (FFAR2-NLRP3 inflammasome axis) in neutrophils triggered by acetate. Secretion of IL-22 by ILC3s | Protection | Fachi et al. ( | ||
|
| Dectin-3 deficiency, IL-7 production, and HIF-1α-dependent glycolysis in macrophages. Induction of IL-22 by ILC3s through STAT3 and AhR | CAC (colitis-associated colon cancer) progression | Zhu et al. ( | |
|
| Regulation of ILC3s by mTOR | Protection | Blanda Di Luccia et.al. ( | |
| Induction of IL-22 via FFAR2 and FFAR3 in ILC3s by butyrate | Protection | W. Yang et al. ( | ||
| Production of IL-22 in ILC3s modulated by atRA-HIC1 axis | Protection | K. Burrows et al. ( | ||
| Production of IL-22 in ILC3s modulated by Vitamin D-Cyp27B1 axis | Protection | Y. Lin et al. ( | ||
| Regulation of ILC3 role and migration by ARNTL (master circadian activator) | Protection | Godinho-Silva et al. ( | ||
| Inhibition of IL-22 secretion by ILC3s through VIPR2 | Susceptibility | J. Talbot et al. ( | ||
| Regulation of ILC3s by TL1A | Protection | J.Castellanos et al. ( | ||
| Regulation of ILC3 migration by the expression of GPR183 | Migration-Protection | C. Chu et al. ( | ||
| Secretion of IL-22 by ILC3s triggered by NKR-P1B | Protection | E. Abou-Samra et al. ( | ||
| Inhibition of IL-17 and IL-22 secretion by ILC3s through RANK-RANKL interaction | Susceptibility | J. Bando et al. ( | ||
| Regulation of ILC3 maintenance by AhR | Protection | S. Li et al. ( | ||
| M1 macrophage type induced by GM-CSF-mediated ILC3s | Protection | T. Castro-Dopico et al. ( | ||
| Pathogen-specific IgA limitation driven by CCR6+ILC3s and TfH cells interaction through MHC-II | Checkpoint: Quality and magnitude control of T-dependent IgA | Melo-Gonzalez et al. ( |